Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HVTN 105: DNA-HIV-PT123 and AIDSVAX B/E in Healthy Adults
NCT02207920Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jul 2014
- Primary completion
- Dec 2015
- Modality
- Prophylactic Vaccines, Recombinant Proteins and Enzymes, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of DNA-HIV-PT123 and AIDSVAX B/E in human immunodeficiency virus infection (HIV) (4 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Frequency of local and systemic reactogenicity signs and symptoms at Month 12, Laboratory measure of safety (CBC, ALT, Creatinine) at Month 12 and 4 more. Started Jul 2014; status: completed.
02
Drugs
DNA-HIV-PT123AIDSVAX B/E
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02207920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02207920.